ReviewJAC-antimicrobial resistance2024
Multidrug-resistant organism bloodstream infections in solid organ transplant recipients and impact on mortality: a systematic review.
Review in JAC-antimicrobial resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Real-world effectiveness and treatment costs of ceftazidime-avibactam versus colistin-meropenem for ICU-acquired MDR gram-negative infections in liver transplant recipients.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Multidrug resistant bacterial infection in liver transplant recipients: A Deterrent and obstacle.Pakistan journal of medical sciences · 2026Article
- The gut microbiome in solid-organ and haematopoietic-stem-cell transplantation.Nature reviews. Microbiology · 2026Review
- Antimicrobial Consumption and Resistance Dynamics Across Healthcare Level: Global Evidence and Stewardship Implications.Pathogens (Basel, Switzerland) · 2026Review
- Geographical variation in the chemical profile and antimicrobial activity ofFrontiers in microbiology · 2026Article
- The species, distribution, resistance of donor-derived pathogens and their impact on solid organ transplant recipients.Frontiers in immunology · 2026Article
- Progress of machine perfusion in managing donor-derived infections in liver transplantation.Translational gastroenterology and hepatology · 2026Review
- Cefiderocol therapy among immunocompromised adult patients: a descriptive analysis from a prospective, multicentre cohort study.BMC infectious diseases · 2025Article
- Epidemiology and Risk Prediction Model of Multidrug-Resistant Organism Infections After Liver Transplant Recipients: A Single-Center Cohort Study.Bioengineering (Basel, Switzerland) · 2025Article
- Successful Treatment of OXA-23Infection and drug resistance · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bloodstream infections (BSIs) cause significant morbidity and mortality in solid organ transplant (SOT) recipients. There are few data regarding the contribution of MDR organisms (MDROs) to these infections. We evaluated the resistance percentage of MDRO BSIs in SOT recipients and the associated mortality. Methods: A systematic review of MEDLINE and Embase databases up to January 2024, for studies of adult SOT recipients that quantified MDRO BSI resistance percentage and/or associated crude mortality. MDROs studied were carbapenem-resistant Enterobacterales (CRE), Results: Of 945 studies identified, 52 were included. Most were retrospective (41/52) and/or single centre (37/52), and liver transplantation was the most frequently studied SOT type (22/52). High resistance percentages of BSIs were noted, ranging from 13.6% CRE for Enterobacterales to 59.2% CRAB for Conclusions: MDRO BSI resistance percentages were high for all pathogens studied (IQR 24.6%-69.4%) but there was geographical and temporal heterogeneity. MDRO BSIs were associated with high mortality in SOT recipients. Microbiological and clinical data in this vulnerable population were incomplete, highlighting the need for robust international multicentre studies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.